Lipid-Based Nanoparticles and Microbubbles – Multifunctional Lipid-Based Biocompatible Particles for in vivo Imaging and Theranostics by Turánek, Jaroslav et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Lipid-Based Nanoparticles and Microbubbles –
Multifunctional Lipid-Based Biocompatible Particles for
in vivo Imaging and Theranostics
Jaroslav Turánek, Andrew D. Miller,
Zuzana Kauerová, Róbert Lukáč, Josef Mašek,
Štěpán Koudelka and Milan Raška
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59870
1. Introduction
1.1. Summary
Lipid-based nanoparticles (LNPs) are both biocompatible and biodegradable so very well
suited to medicinal application in targeted drug delivery and in vivo imaging. Microbubbles
(MB) are another emerging platform for functional delivery of drugs and in vivo imaging. This
chapter is focused on the principles of LNP and MB construction, action and application,
concluding with a section on the medical benefits that may result from bringing LNP and MB
technologies together. Some applications are mentioned in brief to demonstrate the diagnostic
and therapeutic potential of LNPs and MBs. More specific detail on applications is provided
elsewhere in this book.
2. LNP fundamentals
Structural lipids such as cholesterol and glycerophospholipids are the major components of
biological membranes. Without doubt, one of the great triumphs of nature is the manner in
which lipid molecules such as these are able to form into cellular membranes sufficient to
compartmentalize volumes within cells and between cells. In short, lipids are able to form the
vast macromolecular assemblies that come to make up cellular membranes and other barriers
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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in nature precisely because they have an unrivalled capability for self-association, driven by
weak short range forces and the hydrophobic effect (Figure 1) [1]. This capacity for self-
association can be exploited in the laboratory in order to create self-assembly LNPs (approx
100nm in diameter) (Figure 2) that are proving to be a powerful platform to enable the
functional delivery of active pharmaceutical ingredients (APIs) to target cells in vivo. Suitable
APIs might include biopharmaceutical agents (e.g. DNA, RNA interference effectors), selected
small molecule drugs (e.g. anticancer cytotoxic drugs), and/or imaging agents (e.g. magnetic
resonance imaging contrast metals – gadolinium (III) (Gd3+), radiometals, and/or fluorescent
probes). The number of lipid variations is almost limitless, so too the number and variety of
possible LNPs that may be produced for use in biological situations. Therefore, LNPs offer the
potential opportunity for tailor-made preparation and production leading in the future even
to the possibility of LNP-mediated personalized medicine, no less [2, 3].
Figure 1. Principles of lipid structure and self-assembly.
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Structural lipids of all types consist broadly of a non-polar, hydrophobic “chain” or “tail”
region attached to a “polar” or “head” region (a); biological membranes primarily adopt a
normal topology lamellar LαI fluid mesophase (bilayer) structure (b); under certain circum‐
stances biological membranes adopt other mesophases in particular the inverse topology
hexagonal HII fluid mesophase (c), where hydrophobic chain regions face outwards and
hydrophilic polar regions face inwards to form aqueous channels (the darker circles). (Dia‐
grams reproduced from [1])
However, and there always is a however, LNPs that have seen service in vivo are turning out
to have one fundamental design weakness which can be summarized by saying that those
chemical modifications to LNP surfaces that are necessary for such nanoparticles to be stable
to storage and in biological fluids, plus minimally visible to a host immune system, now turn
out to limit the efficiency of functional delivery once LNPs reach their target cells. Accordingly,
one of the primary ways to overcome this problem in recent years has been to introduce the
concept of nanoparticle triggerability to LNP design [2, 4]. Nanoparticles possess triggerability
(or are said to be triggerable) when designed for stability in biological fluids (from a desired
point of administration to disease-target cells) then become triggered for the controlled release
of associated APIs at target cells either through local changes in local endogenous (intrinsic)
conditions, or through the application of an exogenous (extrinsic) stimulus trained onto target
cell regions where nanoparticles are also located. What we are now learning is that MBs used
in combination with ultrasound can be used in with LNPs, to provide a potent way to introduce
LNP triggerability. Moreover, the introduction of ultrasound critically introduces an oppor‐
tunity for real-time, diagnostic imaging of LNP mediated delivery of APIs to target cells in
vivo. Nanoparticles that combine functional API delivery in vivo with real-time, diagnostic
imaging are known as theranostic nanoparticles (TNPs) [5]. Most importantly, TNPs offer the
opportunity for true image-guided therapy. As such this may well be a primary future of the
MBs-ultrasound-LNP combination as the rest of this chapter will now aim to demonstrate.
Figure 2. Functional lipid-based nanoparticle delivery systems.
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In functional lipid-based nanoparticles (LNPs), active pharmaceutical ingredients (APIs) (A)
are condensed within functional concentric layers of chemical components designed for
delivery into cells and intracellular trafficking (B components, primarily lipids and lipid-
related components), biological stability (C stealth/biocompatibility components–typically
Polyethylene Glycol [PEG]) and biological targeting to target cells (D components, biological
receptor-specific targeting ligands) [2, 3].
3. Liposomes to LNPs
Liposomes are the progenitors of all LNPs, and they are formulated directly from lipid
constituents (Figure 3). Liposomes can be prepared by various techniques. The method based
on hydration of lipid film represents the most exploited technique for preparation of lipo‐
somes. The lipids of known molarities are dissolved in organic solution which is subsequently
slowly evaporated in vacuo to produce a thin film. The film is hydrated with a suitable aqueous
buffer at temperature, which is generally above transition temperature of lipids used. Aqueous
buffer contains also compound which are to be entrapped into liposomes. Size of liposomes
can be reduced by freeze-thaw procedure followed by sonication, extrusion, microfluidisation
or high pressure homogenisation. These procedures can tune size distribution of final liposo‐
mal preparation to desired values. The main parameters characterising liposomes are their
size, spherical shape and degree of lamellarity. Liposomes may consist of one bilayer (unila‐
mellar), several bilayers (oligolamellar) or multiple bilayers (multilamellar). Membrane
rigidity can be adjusted using appropriate lipids and membrane fluidity may be controlled
with the use of phospholipids with higher or lower transition temperature.
Figure 3. Various morphological types of liposomes and real appearance in cryoelectron microscopy.
Small unilamellar vesicles (SUV); Large unilamellar vesicles (LUV); Multilamellar vesicles –
concentric (MLV); Multivesicular vesicles (MVV)
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Liposomes are generally formulated on the nm scale and can be further size refined by passage
through physical membrane pores of known size (extrusion). Liposomes are typically charac‐
terised by their size, spherical shape and degree of lamellarity. They may be composed of a
single bilayer (unilamellar), a few bilayers (oligolamellar), or multiple bilayers (multilamellar).
The rigidity of the membrane can also be modified with the use of suitable lipids; and the
fluidity of the membrane may be controlled using phospholipids with higher or lower LαI −
HII mesophase transition temperatures. In general lipids of stearic acids (fully saturated C18
hydrocarbon chains) bestow rigidity to liposome structures (by favouring LαI fluid mesophas‐
es), whilst lipids of oleic acid (Δ9 unsaturated C18 hydrophobic chains) can result in less stable
structures (by favouring HII fluid mesophases). Liposomes have traditionally been used as
some of the very earliest nanodrug delivery vehicles, encapsulating water-soluble drugs
within their central aqueous cavities in order to improve drug pharmacokinetics [6-8].
Liposome spherical diameters can be investigated by using scattered light off the surface of
the particles with photon correlation spectroscopy. Alternatively cryo-TEM can be used to
provide visual images of liposome sizes and shape. The surface charge of liposomes can be
obtained by measuring their zeta potential (electrokinetic potential). Liposome associated
techniques and characteristics have all been employed in more recent time times to prepare
more chemically diverse LNPs.
4. Cellular imaging
Cellular imaging is ”the visualisation of specific cells in an intact animal”. This term also
collectively denotes the visualisation of any type of the entire cell under different conditions
[9]. While cellular imaging applies to the imaging of whole cells, molecular imaging deals with
the visualisation of molecules and sub-cellular components within individual cells [10]. The
exploitation of molecular probes or imaging agents is essential for the use of both cellular and
molecular imaging strategies. Despite the fact that the method of cellular imaging of extrinsic
fluorophores is highly efficient, the depth of tissue from which the signal emitted represents
often a limiting factor for this technique. The possible use of positron emission tomography
(PET) or single–photon computed tomography (SPECT) methods is also limited due to short-
lived radioisotopes and poor spatial resolution. However, three-dimensional images of tissues
containing water can be obtained by magnetic resonance imaging (MRI). This technique is
characterised by high levels of spatial resolution and imaging of depth tissues is achieved.
A primary limitation of MRI is an inherent lack of sensitivity that can be overcome through
the use of contrast agents that enhance signal sensitivity and hence image quality. MRI contrast
agents consist of molecules that incorporate a paramagnetic metal ion, most commonly
gadolinium (III) (Gd3+) or Iron (Fe3+/Fe2+). The improvement in image quality derives from the
modulating effects of the coordinated metal ions on longitudinal (T1) or transverse (T2)
relaxation times associated with proton resonance signals emanating from bulk water mole‐
cules surrounding the coordinated metal ions. Even though contrast agents incorporating Gd3-
increase both 1//T1 and 1/T2 relaxivities, they are commonly used for T1-weighed (positive
bright) contrast imaging, on condition that 1/T1 contribution is higher in tissue than the
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corresponding effect on 1/T2 enhancement. Due to the fact that more considerable increases
in 1/T2 are induced by iron containing contrast agents, they are usually used in T2- weighed
(negative dark) contrast imaging [11]. Despite the most frequently used MRI contrast agents
are thermodynamically and kinetically stable low molecular weight Gd3+ complexes (that
promote MRI contrast by non-specific enhancement of water proton relaxation rates within
the blood pool), there has been a realization of the need for imaging LNPs suitable for the
targeted delivery of imaging agents to sites of disease pathology such as cancerous lesions in
order to obtain clear contrast images of their extent and location.
For cell populations to be imaged by MRI in vivo, these populations must be distinguishable
from natural background noise signal. For this to happen, cells of interest should become
labelled with appropriate agents, making use of controlling mechanisms such as enhanced
permeability and retention (EPR) mechanism for imaging agents to reach target cells [12,13,14],
followed by controlled target cell entry. According to Frangioni et al., the ideal cellular label
should have the following features: a strong signalling effect, good biocompatibility, does not
interfere with cellular genetics, remains retained only in the target cell population, and allows
temporal imaging for long-lasting periods [15]. Controlled target cell entry is preferably by
ligand-specific receptor-mediated cell entry processes, although alternative mechanisms of cell
entry may also be acceptable (Figure 4) [16].
Figure 4. Cell entry mechanisms: the various uptake mechanisms of macromolecules and nanoparticles into cells are
indicated according to their size (Adapted from [14]).
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LNPs are an ideal platform to combine multimodal imaging (e.g. MRI contrast agent and
fluorescent probes) with multiple functionalities in order to effect multimodal cellular
labelling. Targeting of LNPs to various tissues and cells (e.g. tumour) can be accomplished by
conjugation of LNP surfaces with biological receptor-specific targeting ligands (e.g. monoclo‐
nal antibodies, folate, RGD peptides) [2,3]. One of the best examples of such an imaging LNP
recently described in the literature is shown (Figure 5). This imaging LNP system (Gadonano-
F) is a novel Gd3+-containing, imaging LNP system that was designed to act as a folate receptor
(FR)-targeted, positive contrast agent to enable magnetic resonance imaging (MRI) of FR-
presenting cancerous lesions (primary and metastatic) including breast, lung, intestinal, renal,
and ovarian cancers.
Figure 5. Multimodal imaging Gadonano-F LNPs for targeted delivery of MRI contrast agents to tumour cells.
Gadonano-F LNPs are prepared as above with the indicated lipid components. Double
labelling is made possible using gadolinium metallochelating lipid (Gd.DOTA.DSA) for MRI
positive contrast imaging and rhodamine fluorescent probe conjugated lipid (DOPE-Rhoda)
for fluorescence imaging. Folate association with the Gadonano-F LNP surfaces is made
possible using a polyethylene glycol (PEG) lipid (folate-PEG2000-DSPE), ensuring that Gado‐
nano-F LNPs are enabled for FR-specific targeting to tumour cells in vivo. The remaining PEG
lipid (PEG2000-DSPE) ensures that the Gadonano-F LNPs possess stability in biological fluids
(e.g. serum) (see [14]).
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There are a number of pathways by which LNPs could enter mammalian cells, namely by
phagocytosis, pinocytosis, clathrin and calveolin independent endocytosis [9, 17]. Of these,
phagocytosis is a process of engulfing and internalisation of large particles (1 um) by cells. The
majority of phagocytic cells of the immune system, including macrophages, neutrophils,
monocytes, and microglia, are able to internalise foreign bodies via phagocytosis. Pinocytosis
is a method of particle internalisation by non-phagocytic cells but this is a very non-specific
mechanism of internalisation into cells [9]. On the other hand, clathrin-mediated endocytosis
(receptor-mediated) and caveolin-mediated endocytosis are much the more specific means of
cellular entry, of which the first is ideal for entry of LNPs to cells.
In original preclinical laboratory experiments, Gadonano-F LNPs were prepared and used to
image xenograft tumours (IGROV-1) in mice. At just 2h post-injection the Gadonano-F LNPs
mediated a similar signal enhancement to that attained at 24h post-injection by control
(Gadonano LNPs, lacking folate ligand) (Figure 6). Specifically, Gadonano LNPs accumulated
in tumour by the EPR mechanism (“passive” targeting) [12, 13], and labelled cells for MRI over
a period of 24h. These imaging LNPs were seen to access the entire hyperpermeable, living
volume of the tumour while being excluded from the necrotic regions. By contrast, the FR-
targeted Gadonano-F LNPs accumulated in the tumour and labelled cells for MRI from 2h
onwards, owing to EPR mediated tumour uptake from the blood pool followed by rapid FR-
mediated cell entry probably involving clathrin-mediated endocytosis. FR-targeted imaging
LNPs accumulated in more perivascular and macrophage-rich locations [14,18].
 
 
 
μ
Figure 6. Fluorescence microscopy and MRI contrast imaging of 24 h post imaging LNP injection.
On the left 24 h post imaging LNP administration, (a) surface IGROV-1 tumor slices, Gadonano
LNPs, (b) midtumor IGROV-1 slices, Gadonano LNPs, (c) surface IGROV-1 tumor slices,
Gadonano-F LNPs, and (d) IGROV-1 midtumor slices, Gadonano-F LNPs (green bar repre‐
sents 50 μm). On the right, MRI contrast images of IGROV-1 tumour bearing Balb/C nude mice:
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images are from control mice injected with Gadonano LNPs (top); images are of mice injected
with Gadonano-F LNPs (bottom) (white arrow shows location of tumour) (Adapted from [18])
Rapid and effective imaging of FR-bearing tumours by Gadonano-F LNPs in preclinical
experiments, has since led to these LNPs being prepared for clinical trial by GlobalAcorn Ltd
under the name GA101 NANO-GdF (Gadonano LNPs are also being developed for clinical
trial by GlobalAcorn Ltd under the name GA100 NANO-Gd). Rapid and specific imaging of
diseased tissues and tumours will be of paramount importance for preclinical research and
also future diagnostic and theranostic applications in clinic [2, 3].
5. Microbubbles (MBs)
Since the MBs were first proposed as suitable tools for ultrasound contrast agents more than
three decades ago, there has been a remarkable progress in the field. In accordance with that,
the research has been particularly concerned with the MB preparation techniques and their
standardization, in order to ensure a steady composition and size distribution of MBs, both
representing crucial features for the stability of MBs in vivo and thus providing a sufficient
backscatter for ultrasound imaging. Although the very first MBs were generally considered to
contribute to improvement of the imaging techniques, they were soon proved to serve as
excellent drug and gene delivery systems both in diagnostics and therapy. Much has been
discussed on ultrasound molecular imaging using MBs as contrast agents, including novel
preparation techniques and their general design; however, the choice of a convenient system
for drug and gene delivery and concept of MB functionalization is still an issue worth
consideration. In this chapter, potential ways for application of MBs as contrast agents together
with drug and gene delivery are shown, relating to the recently used functionalized MBs in
vitro and in vivo.
MBs are small gas-filled microspheres whose size typically ranges between 1 and 10 µm in
diameter see (Figure 7). They comprise a gas-filled core, usually formed by inert, high
molecular gases such as sulphur hexafluoride or perfluorocarbons, which due to their
decreased solubility and low diffusion prolong the lifespan of MBs in circulation [19], by means
of a stabilizing shell of lipid, polymer and/or protein [20, 21]. The composition of the shell
determines the stiffness and therefore the stability of MBs in blood flow, where instability is
caused by exposure of MBs to the rigors of systemic circulation [19, 22]. Limits on stability can
affect the scope of ultrasound imaging utilization in vivo since the half-life of MBs depends on
their stability. Generally, lipid shelled MBs are considered thinner and more flexible, whilst
polymer and protein-shelled bubbles have a thicker and more rigid shell [23]. A thick perme‐
able shell is beneficial to enhance the MB stability (also reducing the gas diffusion) and thus
might be used for ultrasound drug delivery purposes [19, 24, 25]. However, the shell ought to
only slightly limit the vibration of MBs in the ultrasound field generated by echo imaging
systems (otherwise they do not provide sufficient contrast).
Another important aspect for any MB formulation is their size distribution that dictates the
acoustic properties of MBs [22]. As the MBs smaller than 1 µm in diameter produce minimal
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acoustic contrast, the intent is to produce larger MBs [26-29]. On the other hand, the MB size
distribution should not exceed 10 µm of size in diameter; otherwise they get quickly filtered
by the lungs and can pose a risk of embolus [22, 30]. Furthermore, the size distribution is also
believed to affect the drug delivery [22, 31, 32].
6. Ultrasound imaging
In the field of molecular imaging, ultrasound represents a unique imaging technique as it
provides real-time images in a non-invasive way using relatively cheap and easily portable
equipment; thus, ultrasonography is considered to be currently most widely used diagnostic
imaging modality [19]. However, since the liquid phase material with low compressibility,
such as blood, scatters the sound waves poorly, contrast agents were proposed to improve the
ultrasound images, offering the following general advantages: a very small intravenous
injection is needed for imaging; and they are composed of non-toxic, biodegradable materials
[30]. There are several types of ultrasound contrast agents, such as liquid emulsions, liposomes,
and gas-filled MBs [33]. MBs will be described in detail in this chapter. Since the MB-based
contrast agents are similar in size and shape to erythrocytes and also rheologically behave
similarly to the blood, they appear to be of utmost convenience for ultrasound imaging
systems, providing bright contrast [30]. Moreover, due to their larger size (compared to lipid
and polymer based nanocarriers), systematically delivered MBs do not extravasate; instead
they remain in circulation until they dissolve or are actively cleared by the mononuclear
phagocyte system (MPS) [21, 34, 35].
Figure 7. Pictures of MB obtained by various imaging techniques.
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a. Light microscopy of DPPC/ DPPC/1% DOGS-NTA-Ni MB with carboxyfluorescein-PE
(1%)
b. The same MBs as in (A) observed by epifluorescence microscopy.
c. TEM of MBs. During desiccation of the sample in the vacuum interior of electron micro‐
scope, the MB are pressed to each other, which results in the deformed polygonal shape
d. SEM picture of lyophilised MBs. Intact MB (black arrows), crushed MB shell (white arrow),
hollow inside of MB (white asterisk). Insert: detail of the surface of lyophilised MB.
(Adapted from [48])
7. MBs in the ultrasound field – Different aspects
When exposed to low acoustic pressures, MBs tend to oscillate in a symmetrical, linear way
[36], which means that their expansion and compression is inversely proportional to the local
ultrasound pressure [37]; the phenomenon is known as a stable cavitation or non-inertial
cavitation [38] and comprises stable, low amplitude oscillations of MBs (Figure 8) [23]. Such
stable oscillations create a liquid flow around the MBs, the so called microstreams, which can
apply a shear stress on cell membranes resulting in a transient opening of the cell membranes,
as the shear stress related to micro streaming is relatively high compared to the shear stress
associated with blood flow [23, 36, 39]. With the driving pressure turning into violent or inertial
cavitation [38, 40], MBs undergo rapid expansion and contraction, which result in a violent
bubble destruction [21]. The collapse of MBs is accompanied by shock waves generated in the
fluid near the MB; furthermore, jet formation may occur, which can both contribute to a cell
membrane perforation and increased permeabilization of blood vessels, thus improving
extravasation of circulating drugs into target cells and tissues [20, 23, 41-44]. This phenomenon
is called sonoporation [45] and has been proved visualisation of the pores by scanning electron
microscopy, showing the pores in the plasma membrane (Figure 9) [46, 47]. Despite initial
belief that inertial cavitation of MBs was required to enhance uptake of low molecular weight
drugs, there is now mounting evidence that these stable oscillations may also stimulate the
intracellular delivery of macromolecular drugs and nanoparticles [36]. Two mechanisms have
been postulated to contribute to the uptake of cell impermeable molecules: the formation of
small pores and endocytosis [46, 49]. Whilst the involvement of endocytosis was shown to be
more extensive for larger molecules, the pore formation is considered the main mechanism for
low-weight molecules, such as dextrans [49]. Moreover, when studied in a single-cell model,
it was reported that a direct contact is needed to induce pore formation by stable cavitation,
as larger distances would hamper direct mechanical cavitating MB and cell membrane and
decrease the influence of microstreaming on the cell membrane (Figure 10) [36, 50-52].
Additionally, MBs facilitate cavitation related phenomena, such as temperature rise and free
radical formation [21, 42, 53]; it is assumed that the free radicals increase the cell membrane
permeability for Ca2+ in primary endothelial cells and cardiomyocytes [54-56].
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Last but not least, acoustic radiation forces that may translate MBs in the direction of the
propagating ultrasound wave should be taken into account [21, 36, 57, 58]. Not only can the
acoustic radiation forces be applied to adhere to a specific target, but they can also help to push
the MBs towards the cell surface and thus stimulate interaction with the cell membrane and
promote drug delivery to specific cells [59-62]. Through acoustic radiation forces, MBs can
squeeze through endothelium and tunnel through soft tissue, possibly increasing the deposi‐
tion of shell-loaded materials beyond the vasculature [21, 63, 64].
 
 
 
 
 
 
 
 
 
production of fragmets ‐ nanoshrapnels
Inertial Cavitation of Lipid-Coated MBs: Ultrasound causes lipid-coated MBs to expand and contract. If the pressure is
below a critical value, called the inertial cavitation threshold, then the bubble undergoes sustained oscillations – stable
cavitation. If the pressure is above the inertial cavitation threshold, then inertial forces govern the collapse; this is typi‐
cally associated with the bubble imploding and breaking into small fragments – nanoshrapnels. The inertial cavitation
threshold pressure depends on the material properties of the lipid coating (e.g., area expansion modulus and surface
tension), which are set by the monolayer composition (lipid chain length, PEG coating, nanoparticle bound to the MB
surface)
Figure 8. Effect of acoustic pressure on MB oscillation and explosion.
 
 
 
 
 
 
 
 
 
 
 
 
    ‐ 
GSEM micrographs of cells after sonoporation and fixation. The cells were insonated with 2.25 MHz and 570 kPa peak
negative pressure pulses in the presence of MBs. (a) MAT B III cells; (b) red blood cells. Adapted from [45]. Arrows
indicate pores in the cell membrane. (http://amazingbubbleworld.blogspot.cz/2012/05/classifications-of-cavita‐
tion.html)
Figure 9. MBs assisted sonoporation of cells.
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Figure 10. Various aspect of haw MBs can effect endothelial cell in capillary vessels.
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8. Commercial preparations
The use of MBs in echocardiography was first reported in 1968 [65]. Since that time great
progress has been done in preparation of MBs for human and veterinary use. The following
three commercial MB agents Optison TM (GE Healthcare, WI, USA), Definity® (Lantheus
Medical Imaging, MA, USA) and SonoVue® (Bracco, Milano, Italy) currently hold the license
for clinical diagnostic applications (Table 1). The size of the commercial MBs in these agents
is usually larger than 1 um with imaging durations being 5-10 min.
MB type Manufacturer Shell material Gas Mean size
(µm)
Concentration
(MB/mL)
MB half life
(min)
OptisonTM GE Healthcare Albumin C3F8 2.0 - 4.5 5-8x108 2.5-4.5
Definity® Lantheus Medical
Imaging
Phospholipid C3F8 1.1 - 3.3 1.2x1010 2-10
SonoVue® Bracco Phospholipid CF6 2.0-8.0 0.9-6x1010 3-6
Table 1. Specifications of commercial and self-made MBs.
9. Multifunctional MBs for ultrasound imaging and theranostics
The concept of therapeutic agents being encapsulated in or conjugated with MBs has been
developed over the past few years. In addition to the synergistic effects of ultrasound and MBs
to enhance the permeability of biological barriers such as cell membranes, small blood vessels,
and the BBB, as discussed above, MBs can serve as protective drug carriers. Drugs can be pre-
incorporated into carriers such as liposomes, micelles, or microspheres, and these structures
can then be easily attached to lipid MBs, usually via avidin-biotin interactions (Figure 11) [66].
Such advanced MB complexes have extremely high drug loading capacities and the advantage
of being able to encapsulate both hydrophilic and hydrophobic drugs. Encapsulating unstable
agents protects them from degradation in blood, thus prolonging their half-lives in vivo,
improving treatment efficacy, and lowering the required dose [67]. Another advantage is that
the encapsulated agents can be released during the ultrasound-triggered MB destruction
process. Chemotherapeutic drugs can thus be directly and specifically delivered to target
tissues via ultrasound-mediated perforations, whereas the uptake of the drugs by non-target
tissues is reduced. The encapsulated agents are conjugated close to the shell of MBs, increasing
the opportunity for microstreams, shock waves, and microjets to drive them toward the tissues
and enhance their uptake in the ultrasound-treated region [68]. Since MBs act as ultrasound
contrast agents, the drug delivery process can also be concurrently monitored by detecting the
drug-loaded MBs [69].
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Plain microbubble  Multifunctional microbubble combined 
functionalised liposomes 
BA  C 
5 µm 
A) Structure of plain MB (upper – schematic picture; bottom – optical microscopy –Nomarski contrast)
B) Functionalised MB with bound liposomes (upper - schematic picture showing various possibility of functionaliza‐
tion and modification; bottom – MB with surface bound liposomes – optical microscopy –Nomarski contrast)
C) Transmission electron microscopy of the functionalised MB with bound liposomes. Black arrow - rupture of MB
shell owing to vacuum in electron microscope; white arrows - liposomes bound onto the surface of MBs. (Adapted
from [48])
Figure 11. Targeted and multifunctional MBs.
10. Targeted MBs
Despite the possibility of employing MBs for targeted ultrasound imaging and drug and gene
delivery using the local ultrasound insonation, attaching targeting ligands on the surface of
MBs, which leads to their accumulation in the target region (Figure 12), makes the MBs even
more specific so that the range of clinical use of MBs is vastly expanded [23]. Owing to their
size, MBs are not supposed to leave the vasculature; thus their use is limited to thrombus,
endothelial cells, atherosclerotic plaques, blood clots, and organs such as spleen and liver [23,
47]. Recently there have also appeared papers referring to the use of MB-enhanced ultrasound
for facilitated brain delivery [70, 71]; although the exact mechanism is still unknown, the
interaction between capillary walls and acoustically driven MBs was found to be one of the
key factors which leads to the disruption of the blood-brain barrier – the main obstacle in the
treatment of neurodegenerative diseases [70, 72]. Since the method is non-invasive, according
to the authors, it could be the way for treatment of such diseases as Parkinson’s disease or
Alzheimer’s disease.
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Figure 12. Passive and active targeting of MBs.
There are different ways how to attach the targeting ligands to the shell of MBs that are generally
distinguished by the method of preparation. The targeting ligand can be either co-incorporat‐
ed in the shell during the MB preparation, or attached to the surface of pre-formulated MBs by
covalent or non-covalent methods [73, 74]. The simplest targeted MB design is based on the use
of a phospholipid, phosphatidylserine, which is incorporated in the MB shell during prepara‐
tion. Due to the fact that phosphatidylserine is a membrane marker of apoptosis, it promotes
the phagocytic uptake of cells and liposomes by Kupffer cells and macrophages [74-76]. While
circulating in the bloodstream, MBs containing phosphatidylserine are actively targeting and
captured by the Kupffer cells in the liver, macrophages in the spleen and active neutrophils in
the areas of inflammation, which is the reason why phosphatidylserine-shell agents are used
to detect the foci that lack active phagocytic capacity, e.g. tumour nods in the liver [73, 77-79].
In these agents, the shell is the ligand (phosphatidylserine); since the molecules of phopshati‐
dylserine are kept together by the hydrophobic, van der Waals, and other intermolecular
interactions, the ligand is attached in a non-covalent manner [73].
Nevertheless, though prepared by straightforward shear-mixing in one simple step, this method
is convenient only for stable ligands, which are able to survive the extreme conditions during
the MB preparations [23]. Particularly some proteins and enzymes might be denatured in the
harsh conditions and might lose binding affinity [73]. Therefore a different approach has been
applied, involving attachment of ligands after MB preparation: non-covalent (strept)avidin-
biotin interaction and covalent binding [23, 73, 80, 81]. Considering the fact that the (strept)avi‐
din-biotin interaction has the strongest effective dissociation constant, it has been the most
widely used technique in biotechnology [82]. Biotin residues might be attached in one single
step to antibodies, carbohydrates and many other targeting ligands, including the MB shell
components [73, 83]. Biotinylated antibodies are abundant and can be easily linked to prema‐
nufactured biotinylated bubbles via a streptavidin linker [84].  Nonetheless,  this coupling
scheme is useful only in preclinical research: streptavidin as a foreign protein is a possible
immunogen which might lead to undesired immune response after multiple injections [85].
Another attractive non-covalent strategy is to use the interaction of a metallochelating lipid
complex, such as nickel-nitrilotriacetyl lipid, with a multiplicity of histidine residues (His-tag)
of a protein [48]. The method offers an easy way to attach a genetically engineered protein to
the MB surface with a His-tag, a commonly applied insert in recombinant protein preparation.
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The advantage of metallochelating complex over protein-ligand complexes, e.g. (streptavidin
– biotin, glutathion – glutathion transferase) consists in its specific binding and very low
immunogenicity, if any [86]. However, except for studies using metallochelating liposomes
[86, 87], very little research has been devoted to this issue in terms of MBs; therefore there still
appears to be a high potential for the His-tag – MB applications in the foreseeable future.
 
Figure 13. Schematic presentation of metallochelating MBs, confocal and electron microscopy of metallochelating MBs
and coupling of proteins with HisTag anchor.
The rGFP-HisTag molecule bound onto the surface of metallochelating liposomes was directly
detected by TEM (A,B). Fluorescence of rGFP was used to prove binding of this protein onto
the MB (C). The binding did not affect the native conformation of rGFP as demonstrated by
the preserved fluorescence characteristics of the protein. Homogenous population of highly
fluorescent rGFP MB was detected by flow cytometry (G). Nonspecific binding of rGFP on
both DPPC liposomes as well as MB lacking DOGS-NTA-Ni was not observed by flow
cytometry and confocal microscopy. Confocal microscopy confirmed co-localisation of bound
rGFP-HisTag (green fluorescence) with the lipids forming MB monolayer. The monolayer was
marked with LisR-PE (red fluorescence) (D, E, F). Confocal microscopy revealed that a small
fraction of MB had also attached liposomes or residual lipid structures of collapsed MB on
their surface (as seen in D, E, F). This is in a good agreement with the electron microscopy data
(D) (Adapted from [48]).
Concerning the covalent coupling methods, the techniques are basically the same as the ones
developed for the attachment of ligands to liposomes [88]. As the covalent coupling does not
require foreign proteins or His-tags (Figure 13), the chances of undesired immune response to
the ligand are low [84]. The simple covalent coupling with the formation of peptide bond
between the carboxyl-carrying MBs and protein aminogroups is achieved by adding carbo‐
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diimide chemistry [89]. First, a carboxyl group is activated with carbodiimide in the presence
of N-hydroxysulfosuccinimide, forming active ester [84]. The resulting ester then reacts with
the protein aminogroup, forming an amide bond. This method is unfortunately unsuitable for
clinical settings as well, as to achieve the desired number of targeting molecules per bubble,
large quantities of expensive antibodies must be added to the reaction mixture, not to mention
that only very few of them are actually coupled by the peptide bonding [73]. An alternative
approach of covalent coupling scheme for antibody attachment to MB surface seems to be thiol-
maleimide chemistry, developed for targeted liposome applications [90]. In this case, malei‐
mide on the shell is coupled with a thiol group on the ligand, forming thiol-ether [74]. This
technique is convenient with respect to a possible oriented coupling; if a ligand has a single
thiol, then a single point attachment to the MB shell should retain affinity of the ligand to this
target [84]. Overall, selective oriented coupling with of thiol-protein with a maleimide-carrying
MB seems more attractive.
Despite the possibility of attaching the ligand directly to the MB surface, it might seem more
suitable to connect the ligand to lipid via an extended spacer arm, such as poly(ethylene glycol)
known as PEG. Up to 30 nm long [91], flexible extended PEG spacer arm separates the ligand
and the anchor from each other [92], so that the spacer arm acts as a “fishing line” [93], improving
the chances of reaching its target and MB adhesion and retention on the receptor-coated surfaces
[73, 92, 94]. On the other hand, similar to the design of long-circulating liposomes, PEG chains,
or PEG chain derivatives, can be incorporated into the shell of MBs in order to form a steric
barrier against coalescence and adsorption of macromolecules, such as antibodies [47, 95]. In
recent papers, the protective role by the PEG chains was shown when the targeting ligand was
attached to shorter PEG chains that were shielded by a PEG overbrush layer (buried-ligand
architecture), significantly increasing the MB in vivo stability, prolonging their circulation life-
time and reducing ligand-mediated immunogenicity; it was also reported that the extent of PEG
protection to depended on the overbrush length [48, 96-99]. PEG overbrush architecture (PEG
- polyethyleneimine with a high degree of substitution) was lately used for complexing and
stabilizing the plasmid as well; as a result, the transfection was significantly enhanced [100].
One of the possible reasons for enhanced drug and gene delivery when PEG overbrush strategy
is applied is the fact that targeting ligands are generally affixed to the free ends of the PEG chains
to direct the MBs to a given target [97], so that the bubbles usually bear thousands of ligands on
their surface. Thus cooperative binding of multiple ligands to a target might increase the affinity
of particles to the target site, boosting the transfection efficacy. A combination of targeted MB
agent BR55 and peptide ligand attached to the bubble shell via a PEG spacer are has even been
applied in a prostate cancer clinical trial [101].
11. Drug- and gene-loading strategies
The main advantage of the use of MB-based particles as a delivery tool for drugs and genes
lies in the dose reduction while maintaining its therapeutic efficacy; the method thus provides
much less toxicity than conventional cytotoxic therapies and at the same time has more
specificity, which has a great potential particularly in cancer treatment [84]. Generally, drugs
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and/or genes can be either (a) co-administered with MBs, (b) enclosed within the MB shell, (c)
incorporated in the MB shell, (d) attached to the surface of the MBs (e) incorporated in
liposomes or nanoparticles that are associated with the MB surface.
11.1. Co-administration of drugs with MBs
In this case, the MBs enhance the permeability of the endothelial wall in different manners; (1)
by rupture of the endothelial wall, so that larger particles such as erythrocytes and polymer
particles are able to extravasate [102]; (2) by MBs causing the temporary membrane opening
when the low pressure is applied [103]; (3) by sonoporation, allowing for radionuclides or
plasmid DNA to pass through [104, 105]. For more detailed description of the mechanisms
concerned, please see the above part “Microbubbles in the Ultrasound Field”.
11.2. Enclosing drugs within the MB shell
Instead of co-injecting drugs and MBs, the bubbles might be modified to contain drugs or DNA
[97, 106-110]. It is virtually possible to load the drugs within the interior of the MBs, which is
very convenient since the drug is completely protected and is not released before applying the
ultrasound [23]. However, since the MBs are relatively small, the space for drug loading is quite
limited. This approach was applied for the first time in 1998 already by the team of Unger, who
used lipid-shelled MB with an addition of paclitaxel containing oil phase. Nonetheless, Unger
reported the methodology seems to be unsuitable for clinical setting for three reasons; firstly,
as the monolayer of the lipid-shelled MB is very thin, only small amount of drug can be loaded;
secondly, this strategy is limited only to hydrophobic drugs; last but not least, due to the very
high mechanical indexes of ultrasound waves necessary for drug release, which resulted only
in 30% of cell death, the in vivo use of such ultrasound setting appears unfeasible [110].
Recently, Kooiman et al. used oil-filled polymer microcapsule model for ultrasound-mediated
delivery of lipophilic drugs; microcapsules with a shell of fluorinated end-capped poly(L-lactic
acid) contained hexadecane oil as a drug-carrier reservoir. At higher diagnostic pressures, the
microcapsules cracked and released the drug [111]. Despite offering a great potential in clinical
use, there are limitations as this approach can be applied only for lipophilic drugs. In another
paper, Tinkov et al. suggested the application of doxorubicin (DOX)-loaded phospholipid MBs
for targeted tumour therapy. DOX as a potent chemotherapy was loaded into the DPPC/DPPG/
PEG2000-DPPE MBs and was tested in a pancreas carcinoma model of the rat. Although an
agglomeration and capillary adhesion with embolisation/occlusion of the pulmonary arteries/
capillaries after intravenous infusion of MBs with any new formulation might appear, in this
case no rat died or showed any signs of pulmonary vascular occlusion [112]. Therefore the
strategy seems suitable for more extensive preclinical therapeutic studies.
11.3. Nucleic acids and MBs
Concerning gene delivery, [113] incorporated plasmid DNA inside the gas core of polymer
MBs, so that the plasmid was even protected from the host nucleases; at the same time high
plasmid load per bubble was achieved [113]. In a recent study, Sun et al. compared the
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transfection efficiency of commercial Definity MBs to modified cationic MBs with longer lipid
chain; as a result, cationic bubbles were binding significantly more DNA, so that multi-fold
enhancement was reached in gene delivery [114]. The results were consistent with the findings
of Panje and Nomikou, et al. and the notion that gene delivery might be augmented with a
higher local DNA concentration [115, 116]. In another study, Florinas et al. designed a non-
viral siRNA gene carrier using a combination of an arginine-grafted bioreducible polymer
(ABP), MBs and ultrasound, for targeting vascular endothelial growth factor (VEGF) in human
ovarian cell line; as a result, MBs in combination with lipoplexes showed significantly higher
loading capacity compared to naked siRNA; furthermore, only siRNA complexes with ABP
and MBs showed significant knock down in human ovarian cell line compared to naked siRNA
when incubated for a short time after sonication treatment [116]. The potential of MBs as gene
carriers is still on its rise, offering a wide range of options by functionalization of the bubbles.
The drugs that have sufficient affinity for the lipid monolayer might be, in principle, incorpo‐
rated directly in lipid-shelled MBs [106]. However, due to the fact that the lipid monolayer is
rather thin, the amount of drug available for incorporation is very low. Furthermore, the thin
shell might not be able to prevent the leakage of drugs from the bubble during their circulation.
Therefore other strategies were developed, such as preparation of MBs with a thick lipid shell
containing triglyceride oil phase and drug dissolved in it [117]. Nevertheless, this approach is
restricted only to hydrophobic fat-soluble drugs, e.g. paclitaxel. A thick polymer shell
represents another variety for drug incorporation suitable for water-soluble materials such as
DNA and proteins.
Electrostatic interactions of the lipids and plasmid DNA (possessing an overall negative
charge) are made possible by the positively charged groups of some synthetic lipids within
the shell [109]. DNA can be loaded on the charged MB shell by simply mixing a plasmid with
the lipid bubbles before use. After insonation, the surface-coupled DNA remains intact and at
the same time is protected against enzymatic degradation [118, 119]. Moreover, the transfection
efficiency is increased by the adherence of DNA to the MBs in comparison with co-adminis‐
tration of MBs and non-adsorbed DNA. At the same time, unbound plasmids should not be
able to penetrate into non-targeted cells and tissues and should be degraded, resulting in high
specificity with a low transfection in non-insonated regions [19]. Nevertheless, in comparison
with the payload of DNA inside the gas core of the bubbles, the loading capacity is restricted
to their surface area, which means that high numbers of MBs must be injected. The develop‐
ment of multi-layered assemblies by sequential adsorption of DNA on the positive MB
template offers another alternative; because DNA can be directly incorporated as an anionic
layer within these assemblies, layer-by-layer methods allow precise control over the loading
(or dose) of DNA by controlling film thickness or the number of layers deposited during the
fabrication. Besides that, these methods are entirely aqueous and, unlike conventional methods
for the encapsulation of DNA in thin polymer films, do not require the use of organic solvents
which residua could be presented in these materials post-assembly. [120].
In conclusion, an important advantage of ultrasound-mediated MB-based transfection is the
ability to attain DNA delivery and expression only in the insonated areas and not in non-
targeted regions. Even if the transfection efficacy is not very high but the encoded protein is
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produced in the target tissue in an amount sufficient to achieve functional biological response,
therapeutic intervention should meet its success [121]. Considering the improvement of
transfection efficacy via implementation of viral particles using positively charged assemblies,
a significant transfection was observed [122]. However, one should be always careful since
undesired immune responses after systemic administration might appear.
11.4. Incorporation of drug loaded LNPs with MBs
An intensive research has been devoted to the development of nanocarrier-MB hybrids,
wherein drug-containing LNPs are physically attached to the surface of MB [21]. These hybrids
therefore possess a high drug loading capacity of the nanocarriers and the systemic targeting
capability and vascular permeabilizing effect of bubbles. Lum et al. were the first to attach
loaded LNPs to MBs via avidin-biotin interaction; they reported on biotinylated lipid MBs to
which avidinylated polystyrene beads were attached [117]. The biotinylated MBs were
prepared by inclusion of DSPE-PEG-biotin in the lipid shell. Since up to 105 LNPs were bound
to each of the bubbles, the drug loading capacity is reasonably enhanced [106]. LNPs seem
highly advantageous as (1) they have been long proved as versatile drug delivery systems; (2)
a plethora of knowledge is available on LNPs for drug delivery; (3) some LNPs are perfectly
and already used in clinical practice. They might also enclose both amphiphilic and hydro‐
phobic drugs in their lipid bilayer, as well as hydrophilic drugs in an aqueous core. Never‐
theless, owing to the fact that biotin-avidin linkage might develop an undesired immune
response, this approach is not suitable for clinical use. Therefore Geers et al. prepared doxor‐
ubicin (DOX)-LNPs loaded MBs containing pDNA or siRNA that in combination with
ultrasound boosted both DOX cytotoxicity and pDNA and siRNA delivery to the cells in vitro
[108, 119, 123, 124]. In their last work, Geers et al. developed a self-assembly of functionalized
phospholipids, DOX-loaded LNPs and perfluorobutan gas [125]. Compared to the other
methods discussed above to load MBs with drugs, this strategy seems the most advantageous
from the loading capacity point of view; though it was estimated that approximately 600 to
1300 LNPs might be bound per singe MB, the amount of loaded DOX is still rather limited. On
the other hand, Klibanov et al. prepared liposome-MB pendants incorporating calcein, a
hydrophilic self-quenching fluorescent dye, or thrombin, a crucial enzyme of the thrombosis
cascade, and they achieved a significant payload volume – up to several cubic micrometres of
internal liposome aqueous core space per bubble-LNP [126].
A different approach was introduced by Fan et al. who developed a novel DOX-loaded MB
containing super-paramagnetic iron oxide (SPIO) nanoparticles for dual modality imaging and
improved image-guided drug delivery [127]. The authors showed that the delivery of SPIO to
brain tumours was improved using magnetic targeting in combination with focused ultra‐
sound. Unfortunately, the improvement of DOX delivery using magnetic targeting was not
the object of assessment. Hernot et al. prepared nanobody-targeted MBs using metabolic and
site-specific biotinylation of nanobodies [128]. The researchers developed a system of carmelid-
derived single-domain antibody-fragments, i.e. molecular tracers, coupled to targeted MBs.
Although they demonstrated the functionality of these modified MBs both in vitro and vivo,
since the biotinylated nanobodies were linked to the surface of biotinylated MBs via strepta‐
vidin linker, these are not suitable for clinical application due to the undesired immune
response.
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11.5. Infusion of MBs
Besides imaging applications, MBs showed to be a suitable tool for therapeutic use, e.g.
targeted drug delivery, gene therapy, thrombolysis, and vascular permeability enhancement
[129]. Certain US-contrast-imaging or therapeutic strategies, such as destruction-reperfusion
or MB-enhanced drug delivery, require a continuous injection of the MBs over several minutes.
Results of previous in vitro, animal, and human studies have shown that continuous infusion
of a US contrast agent can markedly prolong vascular Doppler US enhancement. [130-132].
Most quantitative imaging strategies rely on the ability to administer a consistent dose of
contrast agent. The spatial distribution of MBs inside a syringe varies over time owing to the
buoyancy of the MBs. These changes are rapid and result in significant inhomogeneity in the
concentration and size distribution of the MBs during continuous infusion. The population of
MBs that is pumped from a horizontal syringe outlet differs from the initial population as the
MBs float to the top of the syringe [133]. This effect is often overlooked and underestimated
by experimenters. We believe that this is the main reason for contradictory results published
by several authors that compare bolus versus continuous infusion methods of MB application
[131]. A superior signal contrast of liver metastasis has been achieved by a continuous
application of MBs to patients. US contrast agents for hepatic imaging are traditionally injected
as a bolus.
For i.v. applications, precise concentration and size distribution of MBs is required. Continuous
application of MBs might present a problem, owing to their strong tendency to float and
accumulate directly below the surface. The concentration and size distribution of specific MBs
injected into a patient’s blood vessel can be quite different from the ones in the syringe.Re‐
cently, we have described the device called Infucon for continuous infusion of MBs which
prevents flotation of MBs and their accumulation below the surface. The device has been tested
on New Zealand White rabbits using both commercial Sono-Vue diagnostic MBs and PEGy‐
lated DPPC MBs prepared in our laboratory [48, 134].
The Infucon device consists of several parts: a programmable syringe pump (e.g. LAMBDA
VIT-FIT Brno, Czech Republic) with a syringe filled with SF6, an Infucon stirred vessel
positioned on magnetic stirrer (e.g. Heidolph MR 3000 D, Germany) and fixed in the position
by a holder, and the cannula for application of MBs into the rabbit via ear vein. The schemes
of the device together with its photographs are presented in Figure. 14. The role of the syringe
pump is to force the gas (e.g. SF6) into the Infucon stirred vessel and to inject the MBs into
bloodstream via cannula. The same gas which is used for filling MBs is used in the syringe to
ensure stability of the MBs during the infusion. The main function of the turbine-like stirrer
(which contains two teflon-coated ferrits) is to maintain a uniform dispersion of the MBs in
the solution and to prevent their accumulation to the surface owing to their flotation. The stirrer
is hung up on the collar of the carrying-off capillary outlet. The direction of rotation is selected
to maintain down-stream movement of the fluid and to strip MBs from the surface. The device
itself is designed to be hermetically insulated using an O-ring seal. The cell is made of inert
materials (Teflon®, polypropylene, glass, and Viton®). All parts of the Infucon are compatible
with chemical or heat sterilization. The filter installed in the Infucon head prevents possible
air-born particles from entering the cell. The vial (conical bottom) is filled up with a solution
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of MBs (up to 1.5 mL) via an inlet capillary. The flow rate (usually in the range of 100 - 200 µL/
min) and the time of pump action are programmable parameters. The silicon piston of the
syringe is properly lubricated to ensure very low friction and smooth movement preventing
sudden jumps of the piston resulting in pulsation. A turbine-like stirrer fits the conical bottom
of the vial, therefore very low dead volume of residual MB solution is obtained. The turbine-
like stirrer freely hangs on the fringe of the Teflon outlet capillary. The capillary is tightly
embedded into the Teflon body in order to be prevented from bending. There is also an inlet
aperture for incoming gas in this Teflon body. The gas is delivered from the syringe through
the inlet capillary linked tightly to the head part of the Infucon (Figure 15, 16). The stirred
Infucon cell represents solution of the problem of the continuous infusion of MBs. This device
is independent on mechanical stirring of the infusion syringe. Unlike the system based on the
rotation of the entire syringe, Infucon cell provides a genuinely homogeneous MB dispersion.
The MBs are prevented from flotation by stirring the suspension in a separate cell. The infusion
is driven by inert gas filled in a syringe placed in the infusion pump. The inert gas used both
for filling the MBs and driving the MB infusion is supposed to have stabilizing effect on the
MBs during the process of infusion.
 
(A) Assembled device, (B) Head of the Infucon. (Adapted from [144])
OC – outlet capillary for the infusion of microbubles (connection to the cannula)
IC – inlet capillary for inert gas from a syringe inserted into the syringe pump
O – O-ring
I – inlet for gas
MS – turbine-like magnetic stirrer with blades
C – fringe of the outlet capillary (OC)
Figure 14. Schematic drawing of the stirred continuous injector Infucon and the photograph of the Infucon device.
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 Blue line: gass pushing homogenaous dispersion of MBs
Red line: homogenaous dispesion of MBs driving from Infucon cell into rabbit ear vein via canula
Figure 15. Schematic and real view of the device used for i.v. infusion of MBs into the rabbit.
a. The use of Infucon device during the ultrasound scanning of the rabbit heart.
b. Integration of the Infucon device which is injecting the MB suspension via vena aricularis
into the bloodstream of the rabbit. (Adapted from [144])
12. Medicinal application
Imaging the liver – This clinical application of MBs in radiology is most promising. Some
portion of MBs is taken up by the liver and spleen. The precise mechanism is hitherto uncertain,
but the involvement of the reticulo-endothelial system is probable. In clinical trials, this liver
phase generally lasts about 30 minutes when the licensed agent Levovist is used and a few
hours with some agents. The liver is very well seen with MB-specific imaging models, such as
harmonic imaging, during this phase. The primary practical importance is that numerous focal
liver lesions, especially metastases and hepatocellular carcinoma, appear as defects and the
use of MBs considerably increases their visibility [135-137].
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Imaging the heart – MBs can enhance Doppler flow signals in cardiac ultrasonography, and
this can be useful in several situations, such as detecting valvular stenoses. The left ventricular
cavity is highlighted by MB contrast agents and thus the blood-tissue boundary becomes much
clearer. This is useful in detecting abnormalities in wall motion in a given region, assessment
of ejection fraction, and finding left ventricular thrombus. The evaluation of left ventricular
function is crucial for managing of a number of heart diseases. Both resting and inducible
ischaemia can be accurately diagnosed by real time perfusion imaging in stress echocardiog‐
raphy which can be further enhanced by applying intermittent high power pulses destroying
the majority of the MBs in a scan plane and subsequently watch refilling: the rate at which it
occurs is a measure of microcirculatory flow speed [138].
 
A 
(A) control - an image of the heart without MBs.
(B) Heard filled by MBs during 10 minutes of continual infusion
Figure 16. The sonographs of the rabbit heart before and after the continual infusion of the pegylated micribub‐
bles.Right parasternal long-axis window, 4 - chamber view:LA = left atrium, LV = left ventricle, RA = right atrium, RV
= right ventricle, IVS = intervetricular septum, LVW = left ventricular wall, RVW = right ventricular wall, P = pericardi‐
um - lung interface. (Adapted from [144])
13. Therapeutic applications recent advances in molecular, multimodal and
theranostic ultrasound imaging
The importance of MBs usage in treatment is higher than their use as a diagnostic tool. At
present, the different characteristic features of MBs (various sizes and the types of gases and
shell materials) precondition them for use as targeting drug carriers. MBs can help in drug
delivery in themselves (by acting as “cavitation nuclei”) and as drug carriers for site-specific
treatment. Due to these characteristics they can be employed as drug carriers for treatment of
various diseases, such as inflammation, thrombus, lymph nodes, cancer, angiogenesis and
atherosclerosis [136].
13.1. Gene therapy
The use of MBs in gene therapy is most challenging. The delivery of genetic material to a
selected site represents the main problem in this emerging area. Drug delivery can be poten‐
tiated by ultrasound which creates transient non-lethal perforations in cell membranes
facilitating penetration of large molecules and particles into the cells (“sonoporating”). During
this process, high acoustic power is necessary, which is beyond that permitting for imaging.
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However, in the presence of MBs the amount of required power is substantially reduced
because the MBs decrease the amount of energy needed for the process of cavitation, leading
to MB collapse due to excessive oscillations induced by ultrasound pulses. Furthermore,
cavitation of MBs in capillary beds leads to a capillary permeability increase, thus improving
local access of the released therapeutic drug [139]. The clinical use of virus-based vectors for
gene therapy is limited. This is due to the fact that immune response can be induced by viral
proteins in the target tissue and elicit a strong inflammatory activation of endothelial cells.
However, it has been shown that when e.g. plasmids and antisense oligonucleotides are used
in non-viral delivery vehicles, transfection efficiency is decreased and the expression of the
gene product is transient. Commonly used MB preparation Levovist enhanced the beta-Gal
gene transfection efficiency more than 6-fold and Optison were used for gene transfer to
cardiomyocytes. The transfection efficiencies are significantly higher than that of no MB and
it is similar to Levovist [97, 100, 114].
13.2. Blood-brain barrier
The blood-brain barrier (BBB) is a specialized system of capillary endothelial cells preventing
harmful substances in the blood stream from entering the brain. They also supply the brain
with nutrients necessary for proper brain functioning. The BBB regulates transport through
both tight junctions and metabolic barriers and is often a rate-limiting factor in determining
permeation of therapeutic drugs into the brain. It is a significant obstacle affecting delivery of
both small molecules and macromolecular agents. Despite the fact that a variety of drugs could
be potentially used to treat brain diseases, no method exists that would allow non-invasive-
targeted delivery through the BBB.
Ultrasound can be used to locally deliver a drug or gene to a specific region of interest in the
brain. The benefit of the MB technique is that it can be used on a very small area of the BBB.
MBs are used in combination with ultrasound exposure. The effects of ultrasound can be
focused upon the vasculature to reduce the acoustic intensity required for BBB opening
production. Several pathways of transcapillary passage after ultrasound sonication have been
recognized, including transcytosis, passage through endothelial cell cytoplasmic openings
holeyed by “nanoschrapnels” produced by explosion of MB, opening of tight junctions by
oscillating MBs and free passage through injured endothelium [136, 140, 141].
13.3. Thrombolysis and thrombus destruction
The major cause of death in Western countries is thrombo-occlusive cardiovascular disease,
with acute ST-elevation myocardial infarction (STEMI) being a serious medical condition
leading to high morbidity and mortality. Two main treatment strategies have been developed
during the past years. Their aim is to immediately restore coronary blood flow. In the first
studies it was shown that fibrinolysis may be accelerated by ultrasound alone. Besides that,
fibrinolysis can be even more increased by the addition of MBs which are destroyed by
ultrasound induced high pressure. Three mechanisms leading to this increase have been
proposed. The first is the occurrence of complete stress based on micro-jets formed after the
destruction of the MBs by ultrasound. The second mechanism is the generation of reactive
oxygen species in endothelial cells. The third proposed mechanism is a temperature increase,
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also occurring after the MBs collapse induced by ultrasound exposure. Whereas the full
mechanism still remains to be elucidated, evidence indicates that the use of ultrasound alone
and ultrasound combined with MBs can enhance clot dissolution by creating microholes in
freshly formed thrombi [142, 143].
14. Conclusions
LNPs and MBs are examples of the successful transfer of basic and applied research into
commercial medicinal products. Biocompatibility and biodegradability of LNPs together with
versatility in modification and functionalization are features which put together favour their
application in medicine. Combinations of LNPs and MBs make best use of both technologies
to form new theranostic systems that could form the basis of future advanced therapeutics.
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